Business Context and Reporting Period
This Form 8-K is filed by TransBiotec, Inc. (not SOBR Safe, Inc.) for the reporting period of September 1, 2016. The filing discloses significant changes in corporate governance, including the resignation of key officers and the appointment of an Interim CEO.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to executive compensation and equity grants:
- Executive Retainer: $7,500 per month (conditional).
- Financing Condition: Retainer and additional options are contingent on closing financing of at least $200,000.
- Equity Grant: 1,500,000 stock options granted at an exercise price of $0.0045 per share.
Material Changes
Significant personnel changes occurred on September 1, 2016:
- Resignation: Charles Bennington resigned as President, Chief Financial Officer, and Secretary. He remains on the Board of Directors as Chairman. No disagreements were reported.
- Appointment: Ivan Braiker was appointed Interim Chief Executive Officer, Interim Secretary, and a member of the Board of Directors.
- Unregistered Securities: 1,500,000 options were issued to Mr. Braiker under Section 4(a)(2) of the Securities Act of 1933.
Guidance, Outlook, and Risks
Management Commentary: The company is actively seeking financing. Mr. Braiker's compensation structure is explicitly tied to the company's ability to raise at least $200,000. If successful, he will receive an additional 1,500,000 options.
Risks and Contingencies: The primary contingency identified is the company's ability to secure the $200,000 financing required to trigger executive compensation and additional equity grants. The filing notes that the investor (Mr. Braiker) was accredited and sophisticated, and no solicitation occurred.
Investor Verification Checklist
- Verify the company's current cash position and ability to meet the $200,000 financing threshold required for executive compensation.
- Confirm the status of the 1,500,000 options granted to Ivan Braiker and the terms for the potential additional 1,500,000 options.
- Review the company's capitalization table to assess the dilution impact of the new option grants.
- Monitor for subsequent filings regarding the appointment of a permanent CEO and CFO following the interim period.